These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31916413)

  • 1. Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.
    de Frutos F; Mirabet S; Ortega-Paz L; Buera I; Darnés S; Farré N; Perez B; Adeliño R; Bascompte R; Pérez-Rodón J; Aparicio X; Sutil-Vega M; Soto A; Faraudo M; Cainzos-Achirica M; Manito N
    ESC Heart Fail; 2020 Feb; 7(1):25-35. PubMed ID: 31916413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
    Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
    Kapelios CJ; Lainscak M; Savarese G; Laroche C; Seferovic P; Ruschitzka F; Coats A; Anker SD; Crespo-Leiro MG; Filippatos G; Piepoli MF; Rosano G; Zanolla L; Aguiar C; Murin J; Leszek P; McDonagh T; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2019 Nov; 21(11):1383-1397. PubMed ID: 31132222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
    Maggioni AP; Anker SD; Dahlström U; Filippatos G; Ponikowski P; Zannad F; Amir O; Chioncel O; Leiro MC; Drozdz J; Erglis A; Fazlibegovic E; Fonseca C; Fruhwald F; Gatzov P; Goncalvesova E; Hassanein M; Hradec J; Kavoliuniene A; Lainscak M; Logeart D; Merkely B; Metra M; Persson H; Seferovic P; Temizhan A; Tousoulis D; Tavazzi L;
    Eur J Heart Fail; 2013 Oct; 15(10):1173-84. PubMed ID: 23978433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Differences in Chronic Heart Failure Patients With Reduced Ejection Fraction According to Blood Pressure.
    Veenis JF; Brunner-La Rocca HP; Linssen GCM; Van Gent MWF; Hoes AW; Brugts JJ;
    Circ Heart Fail; 2020 May; 13(5):e006667. PubMed ID: 32370547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman.
    Hanbali DA; Hashmi KA; Za'abi MA; Al-Zakwani I
    Int J Clin Pharm; 2021 Aug; 43(4):878-883. PubMed ID: 33140296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
    ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
    Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
    J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
    DeVore AD; Hill CL; Thomas L; Sharma PP; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Hernandez AF; Fonarow GC
    Circ Heart Fail; 2018 Sep; 11(9):e005400. PubMed ID: 30354360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry.
    De Blois J; Fagerland MW; Grundtvig M; Semb AG; Gullestad L; Westheim A; Hole T; Atar D; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2015 Jan; 1(1):31-6. PubMed ID: 27533962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: insights from the NCDR PINNACLE® registry.
    Allen LA; Tang F; Jones P; Breeding T; Ponirakis A; Turner SJ
    BMC Cardiovasc Disord; 2018 May; 18(1):80. PubMed ID: 29724164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to the ESC Heart Failure Treatment Guidelines in Spain: ESC Heart Failure Long-term Registry.
    Crespo-Leiro MG; Segovia-Cubero J; González-Costello J; Bayes-Genis A; López-Fernández S; Roig E; Sanz-Julve M; Fernández-Vivancos C; de Mora-Martín M; García-Pinilla JM; Varela-Román A; Almenar-Bonet L; Lara-Padrón A; de la Fuente-Galán L; Delgado-Jiménez J;
    Rev Esp Cardiol (Engl Ed); 2015 Sep; 68(9):785-93. PubMed ID: 26003504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.